Skip to main content
Erschienen in: Annals of Surgical Oncology 6/2014

01.06.2014 | Endocrine Tumors

Oncologic Resection Achieving R0 Margins Improves Disease-Free Survival in Parathyroid Cancer

verfasst von: K. M. Schulte, MD, FRCS, N. Talat, BSc (Hons), G. Galata, MD, J. Gilbert, PhD, J. Miell, FRCPE, FRCP, L. C. Hofbauer, MD, A. Barthel, MD, S. Diaz-Cano, MD, PhD, FRCPath, S. R. Bornstein, MD, PhD

Erschienen in: Annals of Surgical Oncology | Ausgabe 6/2014

Einloggen, um Zugang zu erhalten

Abstract

Background

Parathyroid cancer has a poor mid-term prognosis, often because of local recurrence, observed in half of all patients. Modern diagnostic workup increasingly enables a preoperative diagnosis of parathyroid cancer. There is limited evidence that more comprehensive oncologic surgery can reduce the risk of local recurrence. This study aims to identify the best specific surgical approach in parathyroid cancer.

Methods

This observational cohort study comprises 19 consecutive patients who had undergone oncologic or nononcologic resection for parathyroid cancer. Baseline parameters were compared by using univariate analysis; outcomes were assessed by χ 2 testing and Kaplan–Meier statistics.

Results

Fifteen of 19 patients were primarily operated on in our tertiary center between 1996 and 2013, and four were referred for follow-up because of their cancer diagnosis. Patient cohorts defined by histologic R-status were comparable for established risk factors: sex, calcium levels, low-risk/high-risk status, and presence of vascular invasion. Oncologic resections were performed in 13 of 15 patients primarily treated in the center and 0 of 4 treated elsewhere (χ 2 = 5.6; p < 0.01). R0 margins were achieved in 11 of 13 (85 %) undergoing oncologic resection and 1 of 6 (17 %) undergoing local excision (χ 2 = 8.1; p < 0.01). R0 margins and primary oncologic resection were associated with higher disease-free survival rates (χ 2 = 7.9; p = 0.005 and χ 2 = 4.7; p = 0.03, respectively). Revision surgery achieved R0 margins in only 2 of 4 (50 %) of patients.

Conclusions

In parathyroid cancer, a more comprehensive surgery (primary oncologic resection) provides significantly better outcomes than local excision as a result of reduction of R1 margins and locoregional recurrence.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Obara T, Fujimoto Y. Diagnosis and treatment of patients with parathyroid carcinoma: an update and review. World J Surg. 1991;15:738–44.PubMedCrossRef Obara T, Fujimoto Y. Diagnosis and treatment of patients with parathyroid carcinoma: an update and review. World J Surg. 1991;15:738–44.PubMedCrossRef
2.
Zurück zum Zitat Ruda JM, Hollenbeak CS, Stack BC Jr. A systematic review of the diagnosis and treatment of primary hyperparathyroidism from 1995 to 2003. Otolaryngol Head Neck Surg. 2005;132:359–72.PubMedCrossRef Ruda JM, Hollenbeak CS, Stack BC Jr. A systematic review of the diagnosis and treatment of primary hyperparathyroidism from 1995 to 2003. Otolaryngol Head Neck Surg. 2005;132:359–72.PubMedCrossRef
3.
Zurück zum Zitat Hundahl SA, Fleming ID, Fremgen AM, Menck HR. Two hundred eighty-six cases of parathyroid carcinoma treated in the US between 1985–1995: a National Cancer Data Base Report. The American College of Surgeons Commission on Cancer and the American Cancer Society. Cancer. 1999;86:538–44.PubMedCrossRef Hundahl SA, Fleming ID, Fremgen AM, Menck HR. Two hundred eighty-six cases of parathyroid carcinoma treated in the US between 1985–1995: a National Cancer Data Base Report. The American College of Surgeons Commission on Cancer and the American Cancer Society. Cancer. 1999;86:538–44.PubMedCrossRef
4.
Zurück zum Zitat Talat N, Schulte K. Clinical presentation, staging and long-term evolution of parathyroid cancer. Ann Surg Oncol. 2010;17:2156–74.PubMedCrossRef Talat N, Schulte K. Clinical presentation, staging and long-term evolution of parathyroid cancer. Ann Surg Oncol. 2010;17:2156–74.PubMedCrossRef
5.
Zurück zum Zitat Harari A, Waring A, Fernandez-Ranvier G, et al. Parathyroid carcinoma: a 43-year outcome and survival analysis. J Clin Endocrinol Metab. 2011;96:3679–86.PubMedCrossRef Harari A, Waring A, Fernandez-Ranvier G, et al. Parathyroid carcinoma: a 43-year outcome and survival analysis. J Clin Endocrinol Metab. 2011;96:3679–86.PubMedCrossRef
6.
Zurück zum Zitat Schulte KM, Talat N. Diagnosis and management of parathyroid cancer. Nat Rev Endocrinol. 2012;8:612–22.PubMedCrossRef Schulte KM, Talat N. Diagnosis and management of parathyroid cancer. Nat Rev Endocrinol. 2012;8:612–22.PubMedCrossRef
7.
Zurück zum Zitat Sidhu PS, Talat N, Patel P, et al. Ultrasound features of malignancy in the preoperative diagnosis of parathyroid cancer: a retrospective analysis of parathyroid tumours larger than 15 mm. Eur Radiol. 2011;21:1865–73.PubMedCrossRef Sidhu PS, Talat N, Patel P, et al. Ultrasound features of malignancy in the preoperative diagnosis of parathyroid cancer: a retrospective analysis of parathyroid tumours larger than 15 mm. Eur Radiol. 2011;21:1865–73.PubMedCrossRef
8.
Zurück zum Zitat Cavalier E, Daly AF, Betea D, et al. The ratio of parathyroid hormone as measured by third- and second-generation assays as a marker for parathyroid carcinoma. J Clin Endocrinol Metab. 2010;95:3745–9.PubMedCrossRef Cavalier E, Daly AF, Betea D, et al. The ratio of parathyroid hormone as measured by third- and second-generation assays as a marker for parathyroid carcinoma. J Clin Endocrinol Metab. 2010;95:3745–9.PubMedCrossRef
9.
Zurück zum Zitat Caron P, Maiza JC, Renaud C, et al. High third generation/second generation PTH ratio in a patient with parathyroid carcinoma: clinical utility of third generation/second generation PTH ratio in patients with primary hyperparathyroidism. Clin Endocrinol (Oxf). 2009;70:533–8.CrossRef Caron P, Maiza JC, Renaud C, et al. High third generation/second generation PTH ratio in a patient with parathyroid carcinoma: clinical utility of third generation/second generation PTH ratio in patients with primary hyperparathyroidism. Clin Endocrinol (Oxf). 2009;70:533–8.CrossRef
10.
Zurück zum Zitat Rubin MR, Silverberg SJ, D’Amour P, et al. An N-terminal molecular form of parathyroid hormone (PTH) distinct from hPTH(1 84) is overproduced in parathyroid carcinoma. Clin Chem. 2007;53:1470–6.PubMedCrossRef Rubin MR, Silverberg SJ, D’Amour P, et al. An N-terminal molecular form of parathyroid hormone (PTH) distinct from hPTH(1 84) is overproduced in parathyroid carcinoma. Clin Chem. 2007;53:1470–6.PubMedCrossRef
12.
Zurück zum Zitat Schulte KM, Gill A, Barczinski M, et al. Classification of parathyroid cancer. Ann Surg Oncol. 2012;19:2620–8.PubMedCrossRef Schulte KM, Gill A, Barczinski M, et al. Classification of parathyroid cancer. Ann Surg Oncol. 2012;19:2620–8.PubMedCrossRef
13.
Zurück zum Zitat Schulte KM, Talat N, Miell J, et al. Lymph node involvement and surgical approach in parathyroid cancer. World J Surg. 2010;34:2611–20.PubMedCrossRef Schulte KM, Talat N, Miell J, et al. Lymph node involvement and surgical approach in parathyroid cancer. World J Surg. 2010;34:2611–20.PubMedCrossRef
14.
Zurück zum Zitat DeLellis RA, Lloyd RV, Heitz PU, Eng C. Pathology and genetics of tumours of endocrine organs (WHO classification). Lyon: International Agency for Research on Cancer; 2004. DeLellis RA, Lloyd RV, Heitz PU, Eng C. Pathology and genetics of tumours of endocrine organs (WHO classification). Lyon: International Agency for Research on Cancer; 2004.
15.
Zurück zum Zitat Busaidy NL, Jimenez C, Habra MA, et al. Parathyroid carcinoma: a 22-year experience. Head Neck. 2004;26:716–26.PubMedCrossRef Busaidy NL, Jimenez C, Habra MA, et al. Parathyroid carcinoma: a 22-year experience. Head Neck. 2004;26:716–26.PubMedCrossRef
17.
Zurück zum Zitat Montenegro FL, Tavares MR, Durazzo MD, et al. Clinical suspicion and parathyroid carcinoma management. Sao Paulo Med J. 2006;124:42–4.PubMedCrossRef Montenegro FL, Tavares MR, Durazzo MD, et al. Clinical suspicion and parathyroid carcinoma management. Sao Paulo Med J. 2006;124:42–4.PubMedCrossRef
18.
Zurück zum Zitat Lee PK, Jarosek SL, Virnig BA, et al. Trends in the incidence and treatment of parathyroid cancer in the United States. Cancer. 2007;109:1736–41.PubMedCrossRef Lee PK, Jarosek SL, Virnig BA, et al. Trends in the incidence and treatment of parathyroid cancer in the United States. Cancer. 2007;109:1736–41.PubMedCrossRef
19.
Zurück zum Zitat Robbins KT. Classification of neck dissection: current concepts and future considerations. Otolaryngol Clin North Am. 1998;31:639–55.PubMedCrossRef Robbins KT. Classification of neck dissection: current concepts and future considerations. Otolaryngol Clin North Am. 1998;31:639–55.PubMedCrossRef
20.
Zurück zum Zitat Wang CA, Gaz RD. Natural history of parathyroid carcinoma. Diagnosis, treatment, and results. Am J Surg. 1985;149:522–7.PubMedCrossRef Wang CA, Gaz RD. Natural history of parathyroid carcinoma. Diagnosis, treatment, and results. Am J Surg. 1985;149:522–7.PubMedCrossRef
21.
Zurück zum Zitat Iihara M, Okamoto T, Suzuki R, et al. Functional parathyroid carcinoma: long-term treatment outcome and risk factor analysis. Surgery. 2007;142:936–43; discussion 943e1.PubMedCrossRef Iihara M, Okamoto T, Suzuki R, et al. Functional parathyroid carcinoma: long-term treatment outcome and risk factor analysis. Surgery. 2007;142:936–43; discussion 943e1.PubMedCrossRef
22.
Zurück zum Zitat Kebebew E, Arici C, Duh QY, Clark OH. Localization and reoperation results for persistent and recurrent parathyroid carcinoma. Arch Surg. 2001;136:878–85.PubMedCrossRef Kebebew E, Arici C, Duh QY, Clark OH. Localization and reoperation results for persistent and recurrent parathyroid carcinoma. Arch Surg. 2001;136:878–85.PubMedCrossRef
23.
Zurück zum Zitat Cordeiro AC, Montenegro FL, Kulcsar MA, et al. Parathyroid carcinoma. Am J Surg. 1998;175:52–5.PubMedCrossRef Cordeiro AC, Montenegro FL, Kulcsar MA, et al. Parathyroid carcinoma. Am J Surg. 1998;175:52–5.PubMedCrossRef
24.
Zurück zum Zitat Ippolito G, Palazzo FF, Sebag F, et al. Intraoperative diagnosis and treatment of parathyroid cancer and atypical parathyroid adenoma. Br J Surg. 2007;94:566–70.PubMedCrossRef Ippolito G, Palazzo FF, Sebag F, et al. Intraoperative diagnosis and treatment of parathyroid cancer and atypical parathyroid adenoma. Br J Surg. 2007;94:566–70.PubMedCrossRef
25.
Zurück zum Zitat Fernandez-Ranvier GG, Khanafshar E, Jensen K, et al. Parathyroid carcinoma, atypical parathyroid adenoma, or parathyromatosis? Cancer. 2007;110:255–64.PubMedCrossRef Fernandez-Ranvier GG, Khanafshar E, Jensen K, et al. Parathyroid carcinoma, atypical parathyroid adenoma, or parathyromatosis? Cancer. 2007;110:255–64.PubMedCrossRef
26.
Zurück zum Zitat Munson ND, Foote RL, Northcutt RC, et al. Parathyroid carcinoma: is there a role for adjuvant radiation therapy? Cancer. 2003;98:2378–84.PubMedCrossRef Munson ND, Foote RL, Northcutt RC, et al. Parathyroid carcinoma: is there a role for adjuvant radiation therapy? Cancer. 2003;98:2378–84.PubMedCrossRef
Metadaten
Titel
Oncologic Resection Achieving R0 Margins Improves Disease-Free Survival in Parathyroid Cancer
verfasst von
K. M. Schulte, MD, FRCS
N. Talat, BSc (Hons)
G. Galata, MD
J. Gilbert, PhD
J. Miell, FRCPE, FRCP
L. C. Hofbauer, MD
A. Barthel, MD
S. Diaz-Cano, MD, PhD, FRCPath
S. R. Bornstein, MD, PhD
Publikationsdatum
01.06.2014
Verlag
Springer US
Erschienen in
Annals of Surgical Oncology / Ausgabe 6/2014
Print ISSN: 1068-9265
Elektronische ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-014-3530-z

Weitere Artikel der Ausgabe 6/2014

Annals of Surgical Oncology 6/2014 Zur Ausgabe

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

CME: 2 Punkte

Prof. Dr. med. Gregor Antoniadis Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

CME: 2 Punkte

Dr. med. Benjamin Meyknecht, PD Dr. med. Oliver Pieske Das Webinar S2e-Leitlinie „Distale Radiusfraktur“ beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

CME: 2 Punkte

Dr. med. Mihailo Andric
Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.